Table 1.
Clinical data
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age/sex | 63/M | 67/F | 63/M | 52/M | 54/M | 68/M | 64/M | 60/M | 90/F | 55/F | 75/M | 77/M |
| Presenting SCr/eGFR | 2.8/23 | 2/25 | 2.3/29 | 2.4/29 | 1.9/37 | 1.9/35 | 1.5/47 | 1.8/39 | 2.5/18 | 1.2/47 | n/a | 6.9/8 |
| Proteinuria (g/day) | 7 | 3 | 10 | 4.5 | <1 | 1.1 | >3.5 | <1 | 1.7 | 0.8 | n/a | 1.8 |
| Hematuria | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Complement C3 | 55 | 140 | 106 | 111 | n/a | Low | n/a | 99 | 109 | 105 | Normal | low |
| SPEP/IFE | IgG κ | IgG κ | IgG κ | IgG κ | IgG λ | – | IgG κ | – | IgG κ | IgG κ | IgA κ | IgG κ |
| BM biopsy | MGRS | Polyclonal plasmacytosis | MM | MM | MM | n/a | MGRS | n/a | n/a | MM | MGRS | MGRS |
| Follow-up time (months) | 120 | 2 | 24 | 36 | 66 | 17 | 2 | 10 | 36 | 36 | 40 | 24 |
| Follow-up SCr/eGFR | ESRD | 1.83/27 | ESRD | ESRD | ESRD | 1.9/35 | eGFR: 47 | 1.8/37 | 2.4/19 | 0.9/64 | 1.8/37 | ESRD |
SCr, serum creatinine (mg/dL); eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); SPEP, serum protein electrophoresis; IFE, immunofixation electrophoresis; BM, bone marrow; MM, multiple myeloma; MGRS, monoclonal gammopathy of renal significance.